IGC Pharma (NYSE American: IGC) is entering the psychedelic medicine space to develop treatments for neuropsychiatric symptoms in dementia, a move that diversifies its pipeline ahead of completing a Phase 2 trial for Alzheimer's agitation.
The clinical-stage biotechnology company announced it received authorization on April 9, 2026, from Colombia’s Fondo Nacional de Estupefacientes (FNE). According to a company statement, this authorization allows IGC to synthesize, formulate, and conduct development activities with psilocybin at its Bogotá research and development facility.
This new research vertical focused on psychedelic compounds runs parallel to the company's ongoing work in Alzheimer's. IGC is nearing the completion of its Phase 2 CALMA trial, which is evaluating a different therapeutic candidate for managing agitation in Alzheimer's patients. The Colombian authorization provides IGC with a regulated capability to explore novel therapeutic approaches that are gaining significant scientific and investor interest.
For investors, this positions IGC Pharma as a new player in the high-growth psychedelic medicine sector. The move could de-risk the company's R&D pipeline, which has been heavily reliant on the outcome of the CALMA trial. By securing the ability to develop psilocybin-based therapies, IGC may attract new investment and potentially increase its market valuation. The company has not disclosed its cash runway.
This article is for informational purposes only and does not constitute investment advice.
